×
About 33,083 results

ALLMedicine™ Hodgkin Lymphoma Center

Research & Reviews  15,301 results

Classic Hodgkin lymphoma in Guatemalan children of age less than six years: analysis of...
https://doi.org/10.1080/10428194.2021.1885666
Leukemia & Lymphoma; Silva O, Charu V et. al.

Feb 25th, 2021 - Classic Hodgkin lymphoma (cHL) in young children (ages 0-6) is rare in high income countries (HICs) but is more prevalent in low- and middle-income countries (LMICs) like Guatemala. Given that the majority of cHL studies have evaluated adolescent/...

Markers of Follicular Helper T Cells Are Occasionally Expressed in T-Cell or Histiocyte...
https://doi.org/10.1093/ajcp/aqaa249
American Journal of Clinical Pathology; Abukhiran I, Syrbu SI et. al.

Feb 24th, 2021 - Follicular helper T cell (TFH) markers are expressed in angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma of the TFH phenotype (PTCL-TFH). However, differential expression and coexpression of these markers in benign and othe...

Soluble PD-L1 is a promising disease biomarker but does not reflect tissue expression i...
https://doi.org/10.1111/bjh.17362
British Journal of Haematology; Veldman J, Alsada ZND et. al.

Feb 23rd, 2021 - Individually, tissue and soluble markers involved in the programmed cell death protein 1/programmed death-ligand (PD-1/PD-L) axis have been described as biomarkers with clinical value in classical Hodgkin lymphoma (cHL). In the context of the succ...

Pasquini MC, Hu Z-H, Curran K, et al. Real-world evidence of tisagenlecleucel for pedia...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903231
Blood Advances;

Feb 23rd, 2021 - Pasquini MC, Hu Z-H, Curran K, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4(21):5414-5424.|2021||

see more →

Guidelines  111 results

Adult Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq?cid=eb_govdel
National Cancer Institute

Jan 14th, 2021 - More than 75% of all newly diagnosed patients with adult HL can be cured with combination chemotherapy and/or radiation therapy.[2] Over the last five decades, U.S. national mortality has fallen more rapidly for adult HL than for any other maligna...

Lisocabtagene maraleucel CAR T shows durable response in large B-cell NHL
https://www.healio.com/news/hematology-oncology/20200709/lisocabtagene-maraleucel-car-t-shows-durable-response-in-large-bcell-nhl

Jul 8th, 2020 - In updated results of the pilot study, presented during the ASCO2020 Virtual Scientific Program, researchers showed that lisocabtagene maraleucel induced durable response as a second-line treatment in large B-cell non-Hodgkin lymphoma.

Pembrolizumab prolonged PFS vs. brentuximab vedotin in r/r Hodgkin lymphoma
https://www.mdedge.com/hematology-oncology/article/223065/hodgkin-lymphoma/pembrolizumab-prolonged-pfs-vs-brentuximab

May 31st, 2020 - Pembrolizumab treatment significantly improved progression-free survival versus brentuximab vedotin in a recent randomized, phase 3 trial including patients with relapsed or refractory classical Hodgkin lymphoma, an investigator has reported.

CAR-T continues to show durable responses in indolent non-Hodgkin lymphoma
https://www.healio.com/hematology-oncology/lymphoma/news/online/{b5b2d115-7000-4df9-8743-26711c3bbde1}/car-t-continues-to-show-durable-responses-in-indolent-non-hodgkin-lymphoma

May 30th, 2020 - Axicabtagene ciloleucel induced a 93% response rate among patients with relapsed or refractory indolent non-Hodgkin lymphoma, according to interim results of the phase 2 ZUMA-5 trial presented during the ASCO20 Virtual Scientific Program.

CAR T-Cell Therapy Impresses in Indolent NHL
https://www.medpagetoday.com/meetingcoverage/asco/86783

May 30th, 2020 - Almost 100% of patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) responded to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel, Yescarta), data from an ongoing study showed.

see more →

Drugs  79 results see all →

Clinicaltrials.gov  16,495 results

Classic Hodgkin lymphoma in Guatemalan children of age less than six years: analysis of...
https://doi.org/10.1080/10428194.2021.1885666
Leukemia & Lymphoma; Silva O, Charu V et. al.

Feb 25th, 2021 - Classic Hodgkin lymphoma (cHL) in young children (ages 0-6) is rare in high income countries (HICs) but is more prevalent in low- and middle-income countries (LMICs) like Guatemala. Given that the majority of cHL studies have evaluated adolescent/...

Markers of Follicular Helper T Cells Are Occasionally Expressed in T-Cell or Histiocyte...
https://doi.org/10.1093/ajcp/aqaa249
American Journal of Clinical Pathology; Abukhiran I, Syrbu SI et. al.

Feb 24th, 2021 - Follicular helper T cell (TFH) markers are expressed in angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma of the TFH phenotype (PTCL-TFH). However, differential expression and coexpression of these markers in benign and othe...

Expert Point of View: Marco Ruella, MD
https://ascopost.com/issues/february-25-2021-supplement-conference-highlights-ash-2020/epov-marco-ruella/

Feb 24th, 2021 - Marco Ruella, MD, of Perelman School of Medicine and Scientific Director of the Lymphoma Program, University of Pennsylvania, commented on this study on CD58 aberrations: “This is a very important study because it describes a possible new mechanis...

ZUMA-5: Axicabtagene Ciloleucel Elicits Response in Indolent Non-Hodgkin Lymphoma
https://ascopost.com/issues/february-25-2021-supplement-conference-highlights-ash-2020/zuma-5-axicabtagene-ciloleucel-elicits-response-in-indolent-non-hodgkin-lymphoma/

Feb 24th, 2021 - In the phase II ZUMA-5 trial, the cellular immunotherapy axicabtagene ciloleucel led to responses in 92% of patients with indolent non-Hodgkin lymphoma (NHL), researchers reported at the 2020 American Society of Hematology (ASH) Annual Meeting & E...

see more →

News  1,093 results

Remission of Hodgkin Lymphoma After COVID-19
https://www.medscape.com/viewarticle/945856

Feb 15th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Patients with cancer are considered at risk for COVID-19, but in some cases, could the infection be a good thing? A case report of a patient with ...

Anti-CD20 Therapy for Lymphoma Tied to Worse COVID-19 Outcomes
https://www.medscape.com/viewarticle/945496

Feb 8th, 2021 - NEW YORK (Reuters Health) - Lymphoma patients treated with B-cell-depleting anti-CD20 monoclonal antibodies, such as rituximab or obinutuzumab, may have worse outcomes from COVID-19 infection, according to a study from France. "More than 20 years ...

Fast Five Quiz: Waldenström Macroglobulinemia Workup
https://reference.medscape.com/viewarticle/944100

Jan 31st, 2021 - Waldenström macroglobulinemia (WM) is an indolent subtype of non-Hodgkin lymphoma (NHL) that affects small lymphocytes. WM is rare, accounting for approximately 2% of hematologic malignancies with 1500 cases diagnosed per year in the United States...

Adult Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq?cid=eb_govdel
National Cancer Institute

Jan 14th, 2021 - More than 75% of all newly diagnosed patients with adult HL can be cured with combination chemotherapy and/or radiation therapy.[2] Over the last five decades, U.S. national mortality has fallen more rapidly for adult HL than for any other maligna...

First Data for CAR T-cell Therapy in Follicular Lymphoma: ZUMA-5
https://www.medscape.com/viewarticle/942494

Dec 10th, 2020 - For the first time, a chimeric antigen receptor (CAR) therapy has yielded a high response rate among patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL), including patients with follicular lymphoma (FL) and marginal zone lymphom...

see more →

Patient Education  4 results see all →